Company / Accounts Receivable
Charles River Laboratories Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$708.9M
FY2025
5-year range
$642.9M / $780.4M
FY2021-FY2025
Trend
-1.7%
vs FY2024
Sector context
#33 of 137
Health Care
What the data says
Charles River Laboratories's accounts receivable of $709M is higher than 76% of companies in the Health Care sector (FY2025). Declined from $780M to $709M over the past 2 years.
Based on SEC 10-K filings.
$709M in FY2025 with a 5-year CAGR of +2.8%. Top quartile in the Health Care sector.
Declined from $780M to $709M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +2.8%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 137This company $708.9M Sector average $1.3B
▼
-46.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.8%, indicating consistent growth.
- In FY2025, accounts receivable decreased 1.7% year-over-year.
- Ranks #33 out of 137 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $708.9M | -1.7% |
| FY2024 | $720.9M | -7.6% |
| FY2023 | $780.4M | +3.7% |
| FY2022 | $752.4M | +17.0% |
| FY2021 | $642.9M | +4.1% |
| FY2020 | $617.7M | +20.2% |
| FY2019 | $514.0M | +8.8% |
| FY2018 | $472.2M | +9.8% |
| FY2017 | $430.0M | +18.1% |
| FY2016 | $364.1M | +34.8% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026